Efficacy and Safety of NABOTA in Post-stroke Upper Limb Spasticity: A phase 3 multicenter, double-blinded, randomized controlled trial

Botulinum toxin A is widely used in the clinics to reduce spasticity and improve upper limb function for post-stroke patients. Efficacy and safety of a new botulinum toxin type A, NABOTA (DWP450) in post-stroke upper limb spasticity was evaluated in comparison with Botox (Onabotulinum toxin A). A total of 197 patients with post-stroke upper limb spasticity were included in this study and randomly assigned to NABOTA group (n=99) or Botox group (n=98). Wrist flexors with modified Ashworth Scale (MAS) grade 2 or greater, and elbow flexors, thumb flexors and finger flexors with MAS 1 or greater were injected with either drug.
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Source Type: research
More News: Botox | Neurology | Stroke | Study